Revvity Inc. (NYSE:RVTY – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $120.77 and last traded at $120.83, with a volume of 115795 shares traded. The stock had previously closed at $113.75.
Analyst Upgrades and Downgrades
Several equities analysts have commented on the stock. JPMorgan Chase & Co. decreased their target price on shares of Revvity from $96.00 to $90.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Stifel Nicolaus dropped their target price on Revvity from $110.00 to $100.00 and set a “hold” rating for the company in a research report on Wednesday, May 6th. Wolfe Research started coverage on shares of Revvity in a report on Tuesday, June 2nd. They set a “peer perform” rating on the stock. Zacks Research raised Revvity from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 4th. Finally, Barclays upped their price target on shares of Revvity from $95.00 to $105.00 and gave the company an “equal weight” rating in a research report on Thursday, May 7th. Three analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $108.36.
Get Our Latest Analysis on RVTY
Revvity Price Performance
Revvity (NYSE:RVTY – Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, topping analysts’ consensus estimates of $1.21 by $0.20. The firm had revenue of $729.69 million during the quarter, compared to analyst estimates of $702.96 million. Revvity had a return on equity of 8.34% and a net margin of 8.16%.The company’s revenue for the quarter was down 1.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.18 EPS. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, sell-side analysts forecast that Revvity Inc. will post 5.36 earnings per share for the current fiscal year.
Revvity Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 13th. Shareholders of record on Friday, October 23rd will be paid a $0.07 dividend. The ex-dividend date is Friday, October 23rd. This represents a $0.28 annualized dividend and a yield of 0.2%. Revvity’s dividend payout ratio (DPR) is 13.33%.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of RVTY. New Mexico Educational Retirement Board boosted its position in Revvity by 1.9% during the 4th quarter. New Mexico Educational Retirement Board now owns 5,416 shares of the company’s stock valued at $524,000 after buying an additional 100 shares during the period. Allworth Financial LP raised its stake in shares of Revvity by 8.9% during the fourth quarter. Allworth Financial LP now owns 1,275 shares of the company’s stock valued at $123,000 after acquiring an additional 104 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Revvity by 17.0% during the first quarter. EverSource Wealth Advisors LLC now owns 749 shares of the company’s stock worth $66,000 after purchasing an additional 109 shares during the period. HighTower Advisors LLC boosted its holdings in shares of Revvity by 2.6% during the fourth quarter. HighTower Advisors LLC now owns 5,141 shares of the company’s stock worth $497,000 after purchasing an additional 129 shares during the period. Finally, Cary Street Partners Financial LLC grew its stake in shares of Revvity by 1.6% in the fourth quarter. Cary Street Partners Financial LLC now owns 8,941 shares of the company’s stock worth $865,000 after purchasing an additional 141 shares during the last quarter. Hedge funds and other institutional investors own 86.65% of the company’s stock.
Revvity Company Profile
Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.
Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.
Read More
- Five stocks we like better than Revvity
- Datavault AI Locks Down CyberCatch in $94M Security Rollup
- Quantum Stocks Are Starting to Choose Sides: Should Investors Do the Same?
- AeroVironment Hit a Bottom in Q2—Can It Take Flight in Q3?
- The Pre-IPO Playbook: How to Cash in on Anthropic Before the Bell
Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.
